Lifesci Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lifesci capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lifesci Capital Today - Breaking & Trending Today

Avoro Capital Advisors LLC Grows Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)

Avoro Capital Advisors LLC raised its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 133.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,333,333 shares of the company’s stock after buying an additional 1,333,333 shares during the […] ....

New Zealand General , New Zealand , Cantor Fitzgerald , Exchange Commission , Capital International Investors , Jpmorgan Chase Co , Avoro Capital Advisors , Hermes Inc , Capital Research Global Investors , Wellington Management Group , Structure Therapeutics Inc , Structure Therapeutics , Free Report , Capital Advisors , Capital Partners , International Investors , Management Group , Research Global Investors , Lifesci Capital , Get Free Report , Therapeutics Inc , Visit Holdingschannel , Structure Therapeutics Daily ,

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are covering the company, MarketBeat reports. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price […] ....

Ventyx Biosciences , Connor Clark Lunn Investment Management Ltd , Ventyx Biosciences Inc , Wells Fargo Company , Charles Schwab Investment Management Inc , Canaccord Genuity Group , Get Free Report , Genuity Group , Lifesci Capital , Lunn Investment Management , Capital Partners , Bay Capital Management , Schwab Investment Management , Biosciences Stock Down , Get Free , Ventyx Biosciences Daily ,

Perspective Therapeutics, Inc. (NYSE:CATX) Director Purchases $39,941.23 in Stock

Perspective Therapeutics, Inc. (NYSE:CATX) Director Purchases $39,941.23 in Stock
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Robertf Williamson , Taylor Morgan Wealth Management , Royal Bank , Cantor Fitzgerald , Perspective Therapeutics Inc , Investment Counsel Inc , Bleakley Financial Group , Advisory Group , Simplicity Wealth , Perspective Therapeutics , Get Free Report , Director Robert , Financial Group , Morgan Wealth Management , Lifesci Capital , Perspective Therapeutics Daily ,

Simplicity Wealth LLC Makes New $162,000 Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Simplicity Wealth LLC acquired a new position in Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 29,405 shares of the company’s stock, valued at approximately $162,000. Other large investors have also modified their […] ....

Ventyx Biosciences , Ventyx Biosciences Company Profile , Canaccord Genuity Group , Securities Exchange Commission , Tower Research Capital , Norden Group , Hermes Inc , Wells Fargo Company , Simplicity Wealth , Ventyx Biosciences Inc , Jump Financial , Free Report , Research Capital , Investment Management , Biosciences Stock Down , Get Free Report , Genuity Group , Lifesci Capital , Visit Holdingschannel , Ventyx Biosciences Daily ,

Larimar Therapeutics (NASDAQ:LRMR) Receives Market Outperform Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Larimar Therapeutics (NASDAQ:LRMR – Free Report) in a report released on Tuesday, Benzinga reports. They currently have a $25.00 price objective on the stock. Several other brokerages also recently commented on LRMR. Citigroup increased their price objective on Larimar Therapeutics from $4.50 to $10.00 and […] ....

Leerink Partnrs , Entrypoint Capital , Larimar Therapeutics Inc , Virtu Financial , Sg Americas Securities , Larimar Therapeutics Company Profile , Fred Alger Management , Larimar Therapeutics , Free Report , Lifesci Capital , Get Free Report , Fire Capital , Point Capital , Alger Management , Larimar Therapeutics Daily ,